BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8

BRAINSTORM CELL THERAPEUTICS INC.

2023-Q2 EPS reported -$0.27

Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.
Cash $0.75M at June 30; raised $7.5M in July direct offering.
FDA ADCOM for NurOwn BLA scheduled Sep 27; PDUFA target Dec 8, 2023.
Appointed Dr. Bob Dagher as Chief Development Officer and Dr. Kirk Taylor as Chief Medical Officer.
Biomarker data from Phase 3 showed NurOwn lowered neurofilament light, a predictor of clinical benefit in ALS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $5.3 million, EPS Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13.

Period: second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was approximately $5.3 million
EPS: Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13
Result: reported results

Exact text from the filing

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-090892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.